NASDAQ:RGEN - Repligen Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $48.79 +0.02 (+0.04 %) (As of 07/20/2018 04:00 PM ET)Previous Close$48.84Today's Range$48.34 - $49.3352-Week Range$29.56 - $49.33Volume196,398 shsAverage Volume285,591 shsMarket Capitalization$2.09 billionP/E Ratio71.28Dividend YieldN/ABeta0.88 Company ProfileFinancialsAnalyst RatingsEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Repligen Corporation, a bioprocessing company, focuses on the development, manufacture, and commercialization of products used to enhance the interconnected phases of the biological drug manufacturing process worldwide. It manufactures and supplies Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins for use in the downstream purification of monoclonal antibodies; and growth factor products used to supplement cell culture media to increase cell growth and productivity in a bioreactor. The company also provides chromatography products comprising OPUS pre-packed chromatography columns, which are used in the purification of antibodies and recombinant proteins; and OPUS PD smaller-scale columns that are used in the high throughput process development screening, viral validation studies, and scale down validation of chromatography processes. Its chromatography products also comprise ELISA kits, which are analytical test kits to detect the presence of proteins and growth factors; chromatography resins under the CaptivA brand; and liquid chromatography products under the Spectra/Chrom brand. In addition, the company provides filtration products, such as XCell ATF systems that are filtration devices used in upstream processes to remove cellular metabolic waste products during the course of a fermentation run, freeing healthy cells to continue producing the biologic drug of interest; Sius TFF line of cassettes used in downstream biologic drug purification and formulation processes; KrosFlo line of hollow-fiber cartridges and TFF systems; Spectra/Por portfolio of laboratory and process dialysis products; and Pro-Connex single-use hollow-fiber module-bag-tubing sets. Repligen Corporation sells its bioprocessing products to life sciences companies, biopharmaceutical companies, and contract manufacturing organizations. The company was founded in 1981 and is headquartered in Waltham, Massachusetts. Receive RGEN News and Ratings via Email Sign-up to receive the latest news and ratings for RGEN and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryBiotechnology SectorMedical SymbolNASDAQ:RGEN CUSIP75991610 Webwww.repligen.com Phone781-250-0111 Debt Debt-to-Equity Ratio0.17 Current Ratio12.22 Quick Ratio10.25 Price-To-Earnings Trailing P/E Ratio71.28 Forward P/E Ratio69.70 P/E Growth3.2 Sales & Book Value Annual Sales$141.24 million Price / Sales15.09 Cash Flow$0.8805 per share Price / Cash55.41 Book Value$13.58 per share Price / Book3.59 Profitability EPS (Most Recent Fiscal Year)$0.69 Net Income$28.35 million Net Margins18.48% Return on Equity6.06% Return on Assets4.69% Miscellaneous Employees476 Outstanding Shares43,690,000Market Cap$2,093.81 Repligen (NASDAQ:RGEN) Frequently Asked Questions What is Repligen's stock symbol? Repligen trades on the NASDAQ under the ticker symbol "RGEN." How were Repligen's earnings last quarter? Repligen Co. (NASDAQ:RGEN) posted its quarterly earnings results on Tuesday, May, 8th. The biotechnology company reported $0.17 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.15 by $0.02. The biotechnology company had revenue of $44.80 million for the quarter, compared to analysts' expectations of $43.88 million. Repligen had a return on equity of 6.06% and a net margin of 18.48%. The company's revenue for the quarter was up 46.4% compared to the same quarter last year. During the same period in the prior year, the business earned $0.15 EPS. View Repligen's Earnings History. When is Repligen's next earnings date? Repligen is scheduled to release their next quarterly earnings announcement on Thursday, August, 2nd 2018. View Earnings Estimates for Repligen. What guidance has Repligen issued on next quarter's earnings? Repligen issued an update on its FY18 earnings guidance on Tuesday, May, 8th. The company provided EPS guidance of $0.69-0.73 for the period, compared to the Thomson Reuters consensus estimate of $0.70. The company issued revenue guidance of $182-188 million, compared to the consensus revenue estimate of $183.48 million. What price target have analysts set for RGEN? 7 Wall Street analysts have issued 12 month price objectives for Repligen's shares. Their predictions range from $40.00 to $56.00. On average, they expect Repligen's share price to reach $46.8333 in the next twelve months. This suggests that the stock has a possible downside of 4.0%. View Analyst Ratings for Repligen. What is the consensus analysts' recommendation for Repligen? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Repligen in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." Who are some of Repligen's key competitors? Some companies that are related to Repligen include AveXis (AVXS), BIO-TECHNE (TECH), Ablynx (ABLYF), China Biologic Products (CBPO), Spark Therapeutics (ONCE), argenx (ARGX), Aerie Pharmaceuticals (AERI), Crispr Therapeutics (CRSP), Halozyme Therapeutics (HALO), Regenxbio (RGNX), Momenta Pharmaceuticals (MNTA), Acceleron Pharma (XLRN), Atara Biotherapeutics (ATRA), Editas Medicine (EDIT) and Solid Biosciences (SLDB). Who are Repligen's key executives? Repligen's management team includes the folowing people: Mr. Anthony J. Hunt, CEO, Pres, Director & Member of Scientific Advisory Board (Age 54)Mr. Jon K. Snodgres, CFO, Sec. & Principal Accounting Officer (Age 52)Mr. Steve Curran, VP of Global OperationsMs. Sondra S. Newman, Sr. Director Investor RelationsMr. Stephen Tingley, VP of Sales Has Repligen been receiving favorable news coverage? Media stories about RGEN stock have trended somewhat positive on Friday, according to Accern. Accern scores the sentiment of press coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Repligen earned a news sentiment score of 0.15 on Accern's scale. They also assigned media headlines about the biotechnology company an impact score of 45.62 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next few days. Who are Repligen's major shareholders? Repligen's stock is owned by many different of institutional and retail investors. Top institutional investors include Conestoga Capital Advisors LLC (3.92%), Fred Alger Management Inc. (1.70%), Summit Creek Advisors LLC (0.35%), Boston Advisors LLC (0.30%), Bank of Montreal Can (0.07%) and Municipal Employees Retirement System of Michigan (0.02%). Company insiders that own Repligen stock include Anthony Hunt, Howard Benjamin, Jon Snodgres, Karen A Dawes, Nicolas Barthelemy, Roy T Eddleman and Thomas F Ryan Jr. View Institutional Ownership Trends for Repligen. Which major investors are selling Repligen stock? RGEN stock was sold by a variety of institutional investors in the last quarter, including Summit Creek Advisors LLC, Municipal Employees Retirement System of Michigan and Bank of Montreal Can. Company insiders that have sold Repligen company stock in the last year include Anthony Hunt, Howard Benjamin, Karen A Dawes, Nicolas Barthelemy, Roy T Eddleman and Thomas F Ryan Jr. View Insider Buying and Selling for Repligen. Which major investors are buying Repligen stock? RGEN stock was acquired by a variety of institutional investors in the last quarter, including Fred Alger Management Inc., Conestoga Capital Advisors LLC, Boston Advisors LLC, Hartford Investment Management Co., Amalgamated Bank and Benin Management CORP. View Insider Buying and Selling for Repligen. How do I buy shares of Repligen? Shares of RGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Repligen's stock price today? One share of RGEN stock can currently be purchased for approximately $48.79. How big of a company is Repligen? Repligen has a market capitalization of $2.09 billion and generates $141.24 million in revenue each year. The biotechnology company earns $28.35 million in net income (profit) each year or $0.69 on an earnings per share basis. Repligen employs 476 workers across the globe. How can I contact Repligen? Repligen's mailing address is 41 SEYON STREET BUILDING 1 SUITE 100, WALTHAM MA, 02453. The biotechnology company can be reached via phone at 781-250-0111 or via email at [email protected] MarketBeat Community Rating for Repligen (NASDAQ RGEN)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 189 (Vote Outperform)Underperform Votes: 194 (Vote Underperform)Total Votes: 383MarketBeat's community ratings are surveys of what our community members think about Repligen and other stocks. Vote "Outperform" if you believe RGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RGEN will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/20/2018 by MarketBeat.com StaffFeatured Article: What does earnings per share mean?